168 related articles for article (PubMed ID: 29869845)
1. Structure-Activity Relationship Studies on (R)-PFI-2 Analogues as Inhibitors of Histone Lysine Methyltransferase SETD7.
Lenstra DC; Damen E; Leenders RGG; Blaauw RH; Rutjes FPJT; Wegert A; Mecinović J
ChemMedChem; 2018 Jul; 13(14):1405-1413. PubMed ID: 29869845
[TBL] [Abstract][Full Text] [Related]
2. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.
Barsyte-Lovejoy D; Li F; Oudhoff MJ; Tatlock JH; Dong A; Zeng H; Wu H; Freeman SA; Schapira M; Senisterra GA; Kuznetsova E; Marcellus R; Allali-Hassani A; Kennedy S; Lambert JP; Couzens AL; Aman A; Gingras AC; Al-Awar R; Fish PV; Gerstenberger BS; Roberts L; Benn CL; Grimley RL; Braam MJ; Rossi FM; Sudol M; Brown PJ; Bunnage ME; Owen DR; Zaph C; Vedadi M; Arrowsmith CH
Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12853-8. PubMed ID: 25136132
[TBL] [Abstract][Full Text] [Related]
3. (R)-PFI-2 Analogues as Substrates and Inhibitors of Histone Lysine Methyltransferase SETD7.
Porzberg MRB; Lenstra DC; Damen E; Blaauw RH; Rutjes FPJT; Wegert A; Mecinović J
ChemMedChem; 2023 Dec; 18(23):e202300457. PubMed ID: 37872124
[TBL] [Abstract][Full Text] [Related]
4. Revealing inhibition difference between PFI-2 enantiomers against SETD7 by molecular dynamics simulations, binding free energy calculations and unbinding pathway analysis.
Niu Y; Shi D; Li L; Guo J; Liu H; Yao X
Sci Rep; 2017 Apr; 7():46547. PubMed ID: 28417976
[TBL] [Abstract][Full Text] [Related]
5. A direct label-free MALDI-TOF mass spectrometry based assay for the characterization of inhibitors of protein lysine methyltransferases.
Guitot K; Drujon T; Burlina F; Sagan S; Beaupierre S; Pamlard O; Dodd RH; Guillou C; Bolbach G; Sachon E; Guianvarc'h D
Anal Bioanal Chem; 2017 Jun; 409(15):3767-3777. PubMed ID: 28389916
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
Lenstra DC; Al Temimi AHK; Mecinović J
Bioorg Med Chem Lett; 2018 Apr; 28(7):1234-1238. PubMed ID: 29519735
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationship studies of LLY-507 analogues as SMYD2 inhibitors.
Zhang B; Liao L; Wu F; Zhang F; Sun Z; Chen H; Luo C
Bioorg Med Chem Lett; 2020 Nov; 30(22):127598. PubMed ID: 33011288
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of SETD7 by PFI-2 attenuates renal fibrosis following folic acid and obstruction injury.
Liu B; Nie J; Liang H; Liang Z; Huang J; Yu W; Wen S
Eur J Pharmacol; 2021 Jun; 901():174097. PubMed ID: 33848540
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of the first fragment hits for SETDB1 Tudor domain.
Mader P; Mendoza-Sanchez R; Iqbal A; Dong A; Dobrovetsky E; Corless VB; Liew SK; Houliston SR; De Freitas RF; Smil D; Sena CCD; Kennedy S; Diaz DB; Wu H; Dombrovski L; Allali-Hassani A; Min J; Schapira M; Vedadi M; Brown PJ; Santhakumar V; Yudin AK; Arrowsmith CH
Bioorg Med Chem; 2019 Sep; 27(17):3866-3878. PubMed ID: 31327677
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic small molecule modulators of histone and DNA methylation.
Hauser AT; Robaa D; Jung M
Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
[TBL] [Abstract][Full Text] [Related]
11. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
[TBL] [Abstract][Full Text] [Related]
13. Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
Alnabulsi SM; Al-Shar'i NA
Future Med Chem; 2019 May; 11(10):1107-1117. PubMed ID: 31280673
[No Abstract] [Full Text] [Related]
14. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment.
Zagni C; Chiacchio U; Rescifina A
Curr Med Chem; 2013; 20(2):167-85. PubMed ID: 23210854
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Methyltransferase Setd7 Allows the In Vitro Expansion of Myogenic Stem Cells with Improved Therapeutic Potential.
Judson RN; Quarta M; Oudhoff MJ; Soliman H; Yi L; Chang CK; Loi G; Vander Werff R; Cait A; Hamer M; Blonigan J; Paine P; Doan LTN; Groppa E; He W; Su L; Zhang RH; Xu P; Eisner C; Low M; Barta I; Lewis CB; Zaph C; Karimi MM; Rando TA; Rossi FM
Cell Stem Cell; 2018 Feb; 22(2):177-190.e7. PubMed ID: 29395054
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer.
Verma SK; Knight SD
Future Med Chem; 2013 Sep; 5(14):1661-70. PubMed ID: 24047271
[TBL] [Abstract][Full Text] [Related]
17. Selective, Small-Molecule Co-Factor Binding Site Inhibition of a Su(var)3-9, Enhancer of Zeste, Trithorax Domain Containing Lysine Methyltransferase.
Taylor AP; Swewczyk M; Kennedy S; Trush VV; Wu H; Zeng H; Dong A; Ferreira de Freitas R; Tatlock J; Kumpf RA; Wythes M; Casimiro-Garcia A; Denny RA; Parikh MD; Li F; Barsyte-Lovejoy D; Schapira M; Vedadi M; Brown PJ; Arrowsmith CH; Owen DR
J Med Chem; 2019 Sep; 62(17):7669-7683. PubMed ID: 31415173
[TBL] [Abstract][Full Text] [Related]
18. The discovery of novel histone lysine methyltransferase G9a inhibitors (part 1): molecular design based on a series of substituted 2,4-diamino-7- aminoalkoxyquinazoline by molecular-docking-guided 3D quantitative structure-activity relationship studies.
Feng T; Wang H; Zhang X; Sun H; You Q
Med Chem; 2014 Jun; 10(4):426-40. PubMed ID: 24151879
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
Kondengaden SM; Luo LF; Huang K; Zhu M; Zang L; Bataba E; Wang R; Luo C; Wang B; Li KK; Wang PG
Eur J Med Chem; 2016 Oct; 122():382-393. PubMed ID: 27393948
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a.
Liu F; Chen X; Allali-Hassani A; Quinn AM; Wasney GA; Dong A; Barsyte D; Kozieradzki I; Senisterra G; Chau I; Siarheyeva A; Kireev DB; Jadhav A; Herold JM; Frye SV; Arrowsmith CH; Brown PJ; Simeonov A; Vedadi M; Jin J
J Med Chem; 2009 Dec; 52(24):7950-3. PubMed ID: 19891491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
